AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

Euronews Tech Talks goes beyond discussions to explore the impact of new technologies on our lives. View on euronews ...